Lorkaserin

Lorkaserin
(IUPAC) ime
	(1R)-8-hloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin
Klinički podaci
Robne marke	Belviq
Identifikatori
CAS broj	846589-98-8
ATC kod	nije dodeljen
PubChem	11658860
ChemSpider	9833595
UNII	637E494O0Z
ChEMBL	CHEMBL360328
Hemijski podaci
Formula	C11H14ClN
Mol. masa	195,688 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1 ; Key: XTTZERNUQAFMOF-QMMMGPOBSA-N
Farmakoinformacioni podaci
Licenca	US FDA:link
Trudnoća	X(US)
Pravni status	℞-only (SAD)
Način primene	Oralno

Lorcaserin (APD-356, Belviq,^[5]^[6], Lorqess^[7]^[8]) je lek protiv gojaznosti. On ima serotonergička svojstva i deluje kao anoreksik. FDA nije odobrila njegovu primenu 2010, zbog zabrinutosti za bezbednost i efikasnost leka.^[9]^[10]

Povezano

Vabicaserin

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948863. edit
↑ „FDA approves Arena obesity drug; first in 13 years”. Reuters. 27. 6. 2012.. Arhivirano iz originala na datum 2014-07-27. Pristupljeno 2014-04-05.
↑ „Belviq”. Trademarkia. 23 Jun 2011. Pristupljeno 27. 6. 2012.
↑ „Lorqess”. EvaluatePharma. 7. 9. 2010.. Arhivirano iz originala na datum 2019-12-14. Pristupljeno 13. 9. 2010.
↑ „Lorqess”. Trademarkia. 25. 3. 2010.. Pristupljeno 13. 9. 2010.
↑ Andrew Pollack (16. 9. 2010.). „F.D.A. Panel Urges Denial of Diet Drug”. New York Times.
↑ „FDA Issues Complete Response Letter for Lorcaserin New Drug Application”. 23. 10. 2010..

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Lorcaserin Homepage Arhivirano 2012-06-25 na Wayback Machine-u

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948863. edit

[reuters-5] „FDA approves Arena obesity drug; first in 13 years”. Reuters. 27. 6. 2012.. Arhivirano iz originala na datum 2014-07-27. Pristupljeno 2014-04-05.

[trademarkia2-6] „Belviq”. Trademarkia. 23 Jun 2011. Pristupljeno 27. 6. 2012.

[evaluatepharma-7] „Lorqess”. EvaluatePharma. 7. 9. 2010.. Arhivirano iz originala na datum 2019-12-14. Pristupljeno 13. 9. 2010.

[trademarkia-8] „Lorqess”. Trademarkia. 25. 3. 2010.. Pristupljeno 13. 9. 2010.

[nytimes-9] Andrew Pollack (16. 9. 2010.). „F.D.A. Panel Urges Denial of Diet Drug”. New York Times.

[prnewswire-10] „FDA Issues Complete Response Letter for Lorcaserin New Drug Application”. 23. 10. 2010..

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]